» Articles » PMID: 17259598

ApoE-/-Fas-/- C57BL/6 Mice: a Novel Murine Model Simultaneously Exhibits Lupus Nephritis, Atherosclerosis, and Osteopenia

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2007 Jan 30
PMID 17259598
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

To establish a mouse model of accelerated atherosclerosis in lupus, we generated apolipoprotein E-deficient (apoE(-/-)) and Fas(lpr/lpr) (Fas(-/-)) C57BL/6 mice. On a normal chow diet, 5 month old apoE(-/-)Fas(-/-) mice had enlarged glomerular tuft areas, severe proteinuria, increased circulating autoantibody levels, and increased apoptotic cells in renal and vascular lesions compared with either single knockout mice. Also, double knockout mice developed increased atherosclerotic lesions but decreased serum levels of total and non-HDL cholesterol compared with apoE(-/-)Fas(+/+) littermates. Moreover, female apoE(-/-)Fas(-/-) mice had lower vertebral bone mineral density (BMD) and bone volume density (BV/TV) than age-matched female apoE(-/-)Fas(+/+) mice. Compared with apoE(-/-)Fas(+/+) and apoE(+/+)Fas(-/-) mice, apoE(-/-)Fas(-/-) mice had decreased circulating oxidized phospholipid (OxPL) content on apoB-100 containing lipoprotein particles and increased serum IgG antibodies to OxPL, which were significantly correlated with aortic lesion areas (r = 0.58), glomerular tuft areas (r = 0.87), BMD (r = -0.57), and BV/TV (r = -0.72). These results suggest that the apoE(-/-)Fas(-/-) mouse model might be used to study atherosclerosis and osteopenia in lupus. Correlations of IgG anti-OxPL with lupus-like disease, atherosclerosis, and bone loss suggested a shared pathway of these disease processes.

Citing Articles

The role of immunoglobins in atherosclerosis development; friends or foe?.

Zhang L, Li P, Li Y, Qu W, Shi Y, Zhang T Mol Cell Biochem. 2024; .

PMID: 39592554 DOI: 10.1007/s11010-024-05158-y.


Human circulating CD24 marginal zone B cells produce IgM targeting atherogenic antigens and confer protection from vascular disease.

Pattarabanjird T, Nguyen A, McSkimming C, Dinh H, Marshall M, Ghosheh Y Nat Cardiovasc Res. 2024; 2(11):1003-1014.

PMID: 39196097 DOI: 10.1038/s44161-023-00356-1.


Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).

Huo R, Yang Y, Huo X, Meng D, Huang R, Yang Y Mol Med Rep. 2024; 30(4).

PMID: 39155862 PMC: 11350626. DOI: 10.3892/mmr.2024.13306.


Autoimmune diseases and atherosclerotic cardiovascular disease.

Porsch F, Binder C Nat Rev Cardiol. 2024; 21(11):780-807.

PMID: 38937626 DOI: 10.1038/s41569-024-01045-7.


Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model.

Kasselman L, Renna H, Voloshyna I, Pinkhasov A, Gomolin I, Teboul I J Tradit Complement Med. 2022; 12(5):447-454.

PMID: 36081818 PMC: 9446105. DOI: 10.1016/j.jtcme.2022.01.006.